TRIAC Therapy Relieves Hyperthyroid Symptoms, Lowering T4, T3, and Metabolic Rate in Resistance to Thyroid Hormone β
TRIAC therapy in RTHβ relieves hyperthyroid symptoms and lowers resting energy expenditure and circulating thyroid hormones without worsening hepatic hormone resistance or exacerbating cardiac thyromimetic activity. Future clinical trials to determine whether TRIAC treatment alters adverse cardiovascular outcomes in this disorder are warranted.
Authors
- Kevin Taylor (ORCID: https://orcid.org/0000-0003-3435-4272)
- Krishna Chatterjee (ORCID: https://orcid.org/0000-0002-2654-8854)
- Julie Martin‐Grace (ORCID: https://orcid.org/0000-0002-0994-3991)
- David Halsall (ORCID: https://orcid.org/0000-0002-2301-6449)
- Susan Oddy
- Laura Watson (ORCID: https://orcid.org/0000-0002-2120-3531)
- Carla Moran (ORCID: https://orcid.org/0000-0002-7318-7166)
- Greta Lyons
Institutions
- University College Dublin (IE)
- Beaumont Hospital (IE)
- Beacon Health System (US)
- Cambridge School (PT)
- Cambridge Quantum Computing (United Kingdom) (GB)
- St. Vincent's University Hospital (IE)
- Wellcome/MRC Institute of Metabolic Science (GB)
- Addenbrooke's Hospital (GB)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1210/clinem/dgaf583
- Citations
- 1
- Primary Topic
- Stress Responses and Cortisol
- Type
- article
- Field-Weighted Citation Impact
- 1.11
Funders
- Wellcome Trust
- National Institute for Health and Care Research
- Medical Research Council
- NIHR Cambridge Biomedical Research Centre